CN113527270A

CN113527270A - Medicine intermediate of PROTAC molecule of targeted monoacylglycerol lipase, preparation method and application

Info

Publication number: CN113527270A
Application number: CN202110808313.XA
Authority: CN
Inventors: 董嘉炜; 刘洋; 汪欣; 尹金龙; 师冰洋; 郑蒙
Original assignee: Henan University
Current assignee: Henan University
Priority date: 2021-07-16
Filing date: 2021-07-16
Publication date: 2021-10-22
Anticipated expiration: 2041-07-16
Also published as: CN113527270B

Abstract

The invention discloses a medical intermediate of a PROTAC molecule of a targeted monoacylglycerol lipase, a preparation method and application, and relates to the field of medicines. It has the structure shown in formula I: formula I:

the hydroxyl end of the protein has reactivity, has the potential of being connected to a linker or other E3 ubiquitin ligase ligands, and is a PROTAC ligand of the ready-to-use type MAGL protein. The invention also discloses a PROTAC molecule of the targeted monoacylglycerol lipase, which has a structure shown in a formula XI.

Description

Medicine intermediate of PROTAC molecule of targeted monoacylglycerol lipase, preparation method and application

Technical Field

The invention relates to the field of medicines, and particularly relates to a medicine intermediate of a PROTAC molecule of a targeted monoacylglycerol lipase, a preparation method and application thereof.

Background

Monoacylglycerol lipase (MAGL) is a serine hydrolase that not only breaks down triacylglycerol into free fatty acids and glycerol in lipid metabolism to supply energy to the body, but also hydrolyzes 2-arachidonic acid glyceride (2-AG) and regulates the signal transduction of the cannabinoid system in vivo. 2-arachidonic acid glyceride is a component of an endocannabinoid system, and endocannabinoids are related to brain injury protection, immune response, inflammatory reaction and the like of an organism; recent studies have shown that the endocannabinoid system inhibits cancer cell proliferation, induces tumor cell apoptosis, and affects tumor angiogenesis during tumor growth in some tumors.

The serine hydrolases belonging to MAGL play a key role in a variety of human physiological processes and diseases, particularly in the digestive, coagulation and complement systems. Due to the considerable research value of the serine hydrolases to which MAGL belongs, a large number of serine hydrolase inhibitors of different structures have been found. The inhibitors can be used as potential therapeutic drugs on one hand and can be used as valuable small molecule probes to research the functions of serine hydrolase on the other hand. However, despite the numerous lead structures found to inhibit serine hydrolases, highly active, highly selective inhibitors are still lacking. At present, no protein targeting degradation drugs aiming at the MAGL exist.

Over the past 10 years, there have been efforts in academia and industry to develop novel MAGL inhibitors, and about 20 small molecule MAGL inhibitors have been reported, mainly including mimetic analogs of 2-AG, an endogenous substrate of MAGL, and various compounds obtained and modified by screening from compound libraries.

Although many MAGL inhibitors have been reported, highly active, highly selective, potent MAGL inhibitors remain elusive.

Proteolytic-targeting chimeras (PROTAC) are compounds linked by two ligands of different functions via a linker. One ligand is used to target a protein of interest (POI), while the other ligand specifically recruits the E3 ligase. When procac binds to E3 ligase and the protein of interest, a ternary complex can be formed, and procac presents the protein of interest in a favorable spatial position to promote ubiquitination of the protein of interest by recruiting E3 ligase, thereby selectively reducing the level of the target protein. The method has the advantages that the PROTAC can be recycled, polyubiquitination of the target protein can be realized, and finally the target protein is degraded by protease, which is the biggest difference between the PROTAC molecule and the small molecule MAGL inhibitor.

JZL184(CAS No: 1101854-58-3) is currently available as an inhibitor of MAGL. The chemical structural formula of the main components is as follows:

at present, JZL184 is not reported to be used for preparing PROTAC so as to inhibit the activity of MAGL enzyme.

In view of this, the invention is particularly proposed.

Disclosure of Invention

The invention aims to provide a medicine intermediate of a PROTAC molecule of a targeted monoacylglycerol lipase, a preparation method and application thereof so as to solve the technical problems.

The inventors structurally transformed JZL184 into a JZL184 analog, providing a JZL184 analog for subsequent use in procac formation. The inventor provides a preparation method of the JZL184 analogue, which is simple and feasible.

The invention is realized by the following steps:

the invention provides a medicine intermediate of a PROTAC molecule of a targeted monoacylglycerol lipase,

formula I:

R²＝H.OH

R³＝H.OH.OCH₃.OEt.F.Cl.Br.I.OCF₃.OAc.NO₂.CH₃.Et

preferably, the pharmaceutical intermediate has a structure represented by formula x:

formula X:

studies have shown that inhibition of the expression of targeted monoacylglycerol lipase (MAGL) proteins has therapeutic implications for a variety of diseases:

(1) the MAGL is closely related to a lipid metabolism network, and can regulate the fatty acid metabolism network through an MAGL-FFA (free fatty acid) pathway, so that the MAGL has positive significance for various metabolic diseases;

(2) in vivo studies have shown that inhibitors of MAGL act to inhibit cannabinoid type i receptor (CB1) in mouse models of inflammation and neuropathic pain;

(3) in 2012, it was confirmed in the mouse model of alzheimer's disease that: inhibition of MAGL can significantly reduce amyloid neuropathology, reduce neuroinflammation and degeneration, and improve synapse and cognitive function;

(4) other studies have found that MAGL inhibitors play a benign role in non-steroidal anti-inflammatory drug-induced gastrorrhagia models and inflammatory bowel disease models;

(5) MAGL is significantly elevated in cells of a variety of diseases, including brain gliomas, liver cancers, malignant melanomas, breast cancers and ovarian cancers, and levels of Free Fatty Acids (FFAs) are elevated. Malignant tumor cells can cause a series of lipid signaling molecule levels such as lysophosphatidic acid (LPA), Lysophosphatidylcholine (LPC), lysophosphatidic acid ethanolamine (LPE), prostaglandin E2(PGE2) to increase through the MAGL-FFA pathway. Wherein, the rising of PGE2 can phosphorylate the downstream Tyr397 site, and then the downstream Tyr397 site is combined with protein receptors and growth factors to promote the transferring and invading ability of cells. Lysophosphatidic acid (LPA) activates multiple G-protein coupled receptors, and promotes the survival and proliferation of tumor cells through different anti-apoptotic signaling pathways.

Therefore, it is particularly necessary to study specific molecules targeting MAGL.

The proteolysis targeting chimera (PROTAC) provides a brand new method for the field of drug research and development, and different from the common small molecule inhibitor, the ligand design of the PROTAC only needs to be combined with the targeting protein, and does not need competitive inhibition, so that inhibition of some targets which are considered as non-druggable in the past and the target of 'undrugable' becomes possible, for example, structural protein and transcription factor can also become the target of the small molecule drug, and only the ligand capable of combining the protein is needed to be made into the PROTAC.

The part (protein binding end molecular ligand) of the PROTAC is the key point of each PROTAC molecule design, and the molecular ligand of the protein to be degraded is characteristic of each PROTAC molecule, so that the optimal design is required according to the specific protein design and the specific molecular ligand.

Based on this, the inventors designed a medical intermediate (i.e., a molecular ligand at the protein-binding end) of a PROTAC molecule that can target monoacylglycerol lipase. The hydroxyl end of the protein has reactivity, has the potential of being connected to a linker or other E3 ubiquitin ligase ligands, and is a PROTAC ligand of the ready-to-use type MAGL protein.

The invention also provides a preparation method of the medical intermediate, which comprises the following steps:

reacting the compound B9 with 3, 4-methylenedioxybromobenzene and n-butyllithium to obtain a compound B4 with a structure shown in a formula III;

reacting the compound B2 with 4-bromophenol, triphenylphosphine and diisopropyl azodicarboxylate to obtain a compound B3 with a structure shown in a formula V;

reacting the compound B3 with n-butyllithium, and then adding the compound B4 to obtain a compound B5 with the structure shown in the formula VI; then carrying out catalytic hydrogenation reaction on the compound B5 to obtain a compound B6 with a structure shown in a formula VII; then reacting the compound B6 with 4-nitrophenol chloroformate to obtain a compound B7 with a structure shown in a formula VIII;

carrying out deprotection reaction to obtain a compound B8 having a structure represented by formula IX;

formula II:

formula III:

formula IV:

formula V:

formula VI:

formula VII:

formula VIII:

formula IX

In other embodiments, the structure of formula I may be obtained by changing the charge and charging the compounds with R1 to R4.

In the preferred embodiment of the application of the invention, N, O-dimethylhydroxylamine hydrochloride, isopropyl magnesium chloride and N-Cbz piperazine-4-ethyl formate are used as substrates to react to obtain a compound B9 with the structure shown in formula II; in the preparation of compound B9, the molar ratio of N, O-dimethylhydroxylamine hydrochloride, isopropyl magnesium chloride and ethyl N-Cbz piperazine-4-carboxylate added was 1-1.2:2-2.2: 1.

in one embodiment, the above molar ratio of addition is 1:2:1, in other embodiments, compound B9 can be prepared in high yield at the above molar ratio of addition.

The compound B9 is prepared by mixing N, O-dimethylhydroxylamine hydrochloride and isopropyl magnesium chloride for reaction at 0-4 ℃, adding N-Cbz piperazine-4-ethyl formate, and separating after the reaction is finished to obtain the compound B9.

Under the condition of low temperature, the reaction can be ensured to be carried out, and the occurrence of side reaction is avoided. Alternatively, the low temperature may be conducted on ice, or in a reaction vessel or reaction apparatus at the reaction temperature.

The above reaction was quenched by water, extracted with ethyl acetate, and the collected organic phase was washed with a saturated sodium bicarbonate solution to remove water-soluble impurities, and then washed with a saturated sodium chloride solution. The organic phase is dried by a drying agent, dried by spinning and subjected to column chromatography to obtain the compound B9.

In other embodiments, compound B9 described above is commercially available.

Optionally, the drying agent may be sodium sulfate, and in other embodiments, the drying agent may also be calcium oxide, silica gel, calcium chloride, or the like.

In a preferred embodiment of the present invention, compound B4 is prepared by: under the atmosphere of nitrogen, 3, 4-methylenedioxybromobenzene and n-butyllithium are mixed and reacted at the temperature of-70 to-80 ℃, then a compound B9 is added, the temperature is raised for reaction, and the compound B4 is obtained by separation.

In another embodiment, the inert gas atmosphere may be selected from an atmosphere such as argon.

At an ultra-low temperature (-70 to-80 ℃) to avoid side reactions.

Preferably, the addition molar ratio of 3, 4-methylenedioxybromobenzene to n-butyllithium to the compound B9 is 1-1.1: 1-1.2: 1; optionally, the molar ratio is 1:1:1, optionally, the molar ratio is 1:1.1: 1.

Preferably, the mixture reacts for 20 to 30min at the temperature of between 70 ℃ below zero and 80 ℃ below zero, and the temperature is increased for 2 to 3 h; optionally, mixing and reacting at-78 ℃ for 30min, and heating for reacting for 2 h.

Preferably, the separation comprises extraction, washing, drying and chromatography; preferably, the extractant is ethyl acetate and the washing is performed with a sodium bicarbonate solution and then with a sodium chloride solution. The unreacted organic reactant is removed by extraction and the solvent is removed from the product by drying.

In the preferred embodiment of the invention, ethylene glycol, imidazole and tert-butyldimethylsilyl chloride are reacted to give compound B2 having the structure shown in formula IV.

Preferably, the preparation of compound B2 comprises: mixing and reacting the added glycol and imidazole with the molar ratio of 1.5-1.6:2-2.2:1 with tert-butyldimethylsilyl chloride, and separating to obtain a compound B2.

In one embodiment, the reaction is followed by dilution with water and extraction with ethyl acetate. Washed first with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give B2.

In one embodiment, the above-mentioned addition molar ratio is 1.5:2:1 or 1.6:2.1: 1.

In one embodiment, compound B2 (structure shown in formula IV) described above is directly commercially available and is not limited to the preparation methods provided herein.

In a preferred embodiment of the present invention, compound B3 is prepared by: under the nitrogen range, the compound B2 is mixed with 4-bromophenol and triphenylphosphine, the mixture is cooled to-4 ℃ to 0 ℃, diisopropyl azodicarboxylate is added, and the compound B3 is obtained by separation after reaction.

In one embodiment, after the addition of diisopropyl azodicarboxylate, the reaction is allowed to slowly warm to room temperature overnight. Quenched by addition of water and extracted with ethyl acetate. Washed first with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B3.

Preferably, compound B2, 4-bromophenol, triphenylphosphine and diisopropyl azodicarboxylate are added in a molar ratio of 1-1.2:1-1.2:2-2.2: 2-2.2.

In a preferred embodiment of the present invention, the preparation of compound B5 comprises: mixing the compound B3 with n-butyllithium under the nitrogen atmosphere and at the temperature of-70 to-80 ℃, and reacting for 30-40 min; then adding the compound B4, heating for reaction, and separating to obtain the compound B5.

Optionally, the separation is sequentially extraction, washing, drying and chromatography.

In one embodiment, extraction is with ethyl acetate. Washed first with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and subjected to column chromatography.

The mixing molar ratio of the compound B3, the n-butyl lithium and the compound B4 is 1-1.1: 1.2-1.3: 1; preferably, compound B3 is reacted with a solution of n-butyllithium in hexane in tetrahydrofuran solvent; preferably, the reaction time after adding the compound B4 is 3-4h, and the temperature is naturally increased, and optionally, the temperature is naturally increased at room temperature.

In a preferred embodiment of the present invention, the preparation of compound B7 comprises: and under the environment of triethylamine and dichloromethane, mixing the compound B6 with 4-nitrophenol chloroformate for reaction, heating for reaction, and separating to obtain a compound B7. Alternatively, the above separation means extraction, washing, drying and chromatography. In one embodiment, extraction is with ethyl acetate. Washed first with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and subjected to column chromatography. Preferably, 4-nitrophenol chloroformate is mixed with compound B6 in a molar ratio of 1.2 to 1.4:1 at 0-4 ℃.

In a preferred embodiment of the present invention, the preparation of compound B8 comprises: mixing the compound B7 with tetrabutylammonium fluoride for reaction to obtain a compound B8;

preferably, the mixing molar ratio of the compound B7 to tetrabutylammonium fluoride is 1: 3-3.2; preferably, the mixing reaction time is 3-4h, and the separation is performed after the mixing reaction.

The invention also provides application of the medical intermediate in preparation of a PROTAC molecule of the targeted monoacylglycerol lipase or an anti-tumor drug.

Tumors include, but are not limited to: brain glioma, hepatocarcinoma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, colorectal cancer, brain secondary tumor, and brain vascular disease. The secondary tumor of the brain is brain metastasis caused by lung cancer, breast cancer, prostatic cancer or colorectal cancer; the cerebral vascular disease is intracranial aneurysm or hypertensive cerebral hemorrhage.

A monoacylglycerol lipase PROTAC protein degradation compound comprising a first ligand and a second ligand, and the first ligand is linked to the second ligand through a linker, and the first ligand has the structure of the above pharmaceutical intermediate or the structure in which a hydroxyl group of the above pharmaceutical intermediate is substituted; the second ligand is an E3 ubiquitin ligase ligand;

monoacylglycerol lipase PROTAC protein degradation compounds have the structure shown in formula XI:

formula XI:

preferably, the second ligand is selected from: a ligand targeting VHL, CRBN, MDM2 or IAPE e3 ubiquitin ligase complex; preferably, the second ligand is selected from the group consisting of ligands of MDM 2; the linker is selected from a linear or branched molecule; preferably, the linker is selected from polyethylene glycol;

preferably, the monoacylglycerol lipase PROTAC protein degrading compound has the structure shown in formula XII:

formula XII:

the secondary ligand structure is not limited to polypeptides, small molecules, aptamers, and the like.

The linker may be any linear or branched molecule according to industry consensus, preferably polyethylene glycol is selected in the examples. E3 ubiquitin ligase ligands and adapters have been widely developed and synthesized, being easily purchased and accessible to the creative primary ligands.

The invention has the following beneficial effects:

the invention designs a medicine intermediate (namely a molecular ligand of a protein binding end) of a PROTAC molecule capable of targeting monoacylglycerol lipase. The hydroxyl end of the protein has reactivity, has the potential of being connected to a linker or other E3 ubiquitin ligase ligands, and is a PROTAC ligand of the ready-to-use type MAGL protein. The invention also discloses a PROTAC molecule of the targeted monoacylglycerol lipase.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.

FIG. 1 shows the NMR spectrum of Compound B8;

FIG. 2 shows the nuclear magnetic hydrogen spectrum result of compound B8;

FIG. 3 is a graph showing the results of the JZL184 molecule docking with MAGL protein;

FIG. 4 is a graph showing the docking results of the B8 molecule with the MAGL protein;

FIG. 5 is a graph showing the results of molecular docking of the MAGL protein (PDB:3HJU) with Protac-1 synthesized from B8;

FIG. 6 is a photograph of a protein electrophoresis strip;

FIG. 7 is a graph showing the results of cell proliferation experiments.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

The features and properties of the present invention are described in further detail below with reference to examples.

Example 1

The embodiment provides a medical intermediate of a ProTAC molecule of a targeted monoacylglycerol lipase, and the synthesis method comprises the following steps:

dissolving 1 equivalent (namely the molar ratio) of N, O-dimethylhydroxylamine hydrochloride in tetrahydrofuran, dropwise adding 2 equivalents of isopropyl magnesium chloride at zero temperature, reacting for 2 hours at 0 ℃, adding 1 equivalent of N-Cbz piperazine-4-ethyl formate, and reacting overnight. Quenched by addition of water and extracted with ethyl acetate. Washed successively with saturated sodium bicarbonate solution and saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B9.

Under nitrogen atmosphere, 1 equivalent of 3, 4-methylenedioxybromobenzene was dissolved in dry tetrahydrofuran, cooled to-78 ℃, and 1.2 equivalents of n-butyllithium in hexane was added dropwise and reacted at-78 ℃ for 30 minutes. A1 equivalent weight solution of compound B9 in tetrahydrofuran was added dropwise thereto, and the mixture was slowly warmed to room temperature and reacted for 3 hours. Quenched by addition of water and extracted with ethyl acetate. Washed with saturated sodium bicarbonate solution and with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B4.

1.5 equivalents of ethylene glycol are dissolved in DMF, 2 equivalents of imidazole are added and 1 equivalent of tert-butyldimethylchlorosilane is added. Stirred at room temperature for 24 hours. Water was added to dilute, and extraction was performed with ethyl acetate. The extracted organic phase is washed with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B2. In other embodiments, CH may be selected₂Cl₂THF instead of DMF.

Under nitrogen atmosphere, 1 equivalent of compound B2 is dissolved in dry tetrahydrofuran, 1 equivalent of 4-bromophenol is added, 2 equivalents of triphenylphosphine are added, the mixture is stirred uniformly, the mixture is cooled to 0 ℃, and 2 equivalents of diisopropyl azodicarboxylate is slowly added dropwise. Slowly warm to room temperature and react overnight. Quenched by addition of water and extracted with ethyl acetate. The extracted organic phase is washed with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B3.

Under a nitrogen atmosphere, 1 equivalent of compound B3 was dissolved in dry tetrahydrofuran, cooled to-78 degrees, and 1.2 equivalents of n-butyllithium in hexane were added dropwise thereto and the reaction was maintained at-78 degrees for 30 minutes. A1 equivalent weight solution of compound B4 in tetrahydrofuran was added dropwise thereto, and the mixture was slowly warmed to room temperature and reacted for 3 hours. Quenched by addition of water and extracted with ethyl acetate. The extracted organic phase is washed with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B5.

Compound B5 was dissolved in methanol, 10% by mass Pd/C (20%) was added, and hydrogen gas was introduced three times to replace it, and the reaction was carried out for 24 hours while maintaining 1 atm of hydrogen gas. The reaction was filtered directly through celite and spin dried to give compound B6.

1 equivalent of compound B6 was dissolved in dry dichloromethane, 2 equivalents triethylamine was added and cooled to 0 ℃. 1.2 equivalents of 4-nitrophenol chloroformate were added, the temperature was slowly raised to room temperature, and the mixture was stirred overnight. Quenched by addition of water and extracted with ethyl acetate. The extracted organic phase is washed with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B7.

1 equivalent of compound B7 was dissolved in tetrahydrofuran, 3 equivalents of tetrabutylammonium fluoride were added, and stirring was carried out for 3 hours. Quenched by addition of water and extracted with ethyl acetate. The extracted organic phase is washed with saturated sodium bicarbonate solution and then with saturated sodium chloride solution. The organic phase is dried over sodium sulfate, spin-dried and column chromatographed to give compound B8.

The hydroxyl group of compound B8 is reactive and can be attached to PEG or other E3 ubiquitin ligase ligands by simple reaction.

The nuclear magnetic carbon spectrum result of the compound B8 is shown in figure 1,¹³C NMR(75MHz,Chloroform-d)δ157.4,156.4,152.1,147.7,146.2,144.7,139.9,139.8,138.1,127.2,125.0,122.3,119.0,114.2,107.8,106.9,101.1,79.2,69.2,60.5,45.1,44.7,44.2,26.7,26.4。

the results of nuclear magnetic hydrogen spectroscopy of compound B8 are shown in figure 2,¹H NMR(300MHz,Chloroform-d)δ8.3–8.1(m,2H),7.4(d,J＝8.8Hz,2H),7.3–7.2(m,2H),7.0–6.7(m,5H),5.9(s,2H),4.3(d,J＝12.5Hz,2H),4.1–3.9(m,4H),3.0(dt,J＝39.9,12.6Hz,2H),2.6–2.4(m,3H),1.5(m,4H)。

experimental example 1

This example provides a computer-chemical molecular simulation test of the binding free energy of compound B8 with MAGL protein. Which comprises the following steps: PBD data were obtained from the protein structure database and optimized for molecular and protein structure using gaussian 16 using the method and basis set B3LYP-D3/6-31g (D), further binding free energy calculations and molecular docking were performed by vina software followed by mapping using pymol software, and molecular interaction sites were labeled using ligapot software.

JZL184 molecule is docked with MAGL protein (PDB:3HJU), B8 molecule is docked with MAGL protein (PDB:3HJU), MAGL protein (PDB:3HJU) and Protac-1 molecule synthesized by B8 molecule are docked separately, and docking result and self-binding energy are detected separately.

The results of JZL184 molecule-to-MAGL protein docking are shown in FIG. 3, and indicate that JZL184 molecule interacts with MAGL protein with a binding free energy of-10.6 kcal/mol.

The results of the docking of B8 molecule with MAGL protein are shown in FIG. 4, which shows that B8 molecule interacts with MAGL protein with a binding free energy of-9.6 kcal/mol.

The Protac-1 molecule is shown below:

results of molecular docking between MAGL protein (PDB:3HJU) and Protac-1 molecule synthesized from B8 molecule are shown in FIG. 5, which shows that the B8 end of Protac-1 molecule has the ability to bind to MAGL protein and the binding free energy is-7.2 kcal/mol.

Experimental example 2

This example was used for protein electrophoresis. Protac-1 molecules are used for treating MT cells of human brain glioma stem cells in culture for 72 hours, the cells are collected in RIPA lysate, protein quantification is carried out by an SDS-PAGE protein electrophoresis system, and the protein is transferred to a PVDF membrane. Blocking with 5% skim milk for 1 hour, followed by antibody incubation at 4 degrees overnight, washing the membrane 3 times for 10 minutes in TBS-T buffer the next day, followed by 1 hour incubation with HRP-labeled secondary antibody, followed by detection of protein bands with ECL luminescence.

As shown in fig. 6, it can be seen from fig. 6 that the concentration-dependent degradation ability of MAGL protein is exhibited by the PROTAC molecule synthesized by B8 in the primary human brain glioma stem cell MT cell. Alpha-tubulin is a cellular loading internal control.

Experimental example 3

In this example, a cell growth experiment was performed. The experimental procedure was as follows: cells were initially counted, 1 ten thousand cells were seeded in 12-well plates, media carrying different concentrations of drug were changed daily, cells were counted at corresponding time points, and plotted against fold of 1 ten thousand cells in the first day. The statistics used t-test.

As shown in fig. 7, it can be seen from fig. 7 that the proliferation of MT and 528NS cells can be inhibited by PROTAC molecules synthesized from MT and 528NS brain glioma stem cells treated with JZL184 and B8 molecules modified by JZL 184. Protac molecules have better consistent effect than JZL184 and are used at lower concentrations.

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A pharmaceutical intermediate of a monoacylglycerol lipase-targeted PROTAC molecule, characterized in that it has the structure of formula I:

formula I:

R²＝H，OH

R³＝H，OH，OCH₃，OEt，F，Cl，Br，I，OCF₃，OAc，NO₂，CH₃，Et

formula X:

2. a process for the preparation of a pharmaceutical intermediate according to claim 1, which comprises:

reacting the compound B3 with n-butyllithium, and then adding the compound B4 to obtain a compound B5 with a structure shown in a formula VI; then carrying out catalytic hydrogenation reaction on the compound B5 to obtain a compound B6 with a structure shown in a formula VII; then reacting the compound B6 with 4-nitrophenol chloroformate to obtain a compound B7 with a structure shown in a formula VIII;

formula II:

formula III:

formula IV:

formula V:

formula VI:

formula VII:

formula VIII:

formula IX

3. The preparation method according to claim 2, characterized in that N, O-dimethylhydroxylamine hydrochloride, isopropyl magnesium chloride and N-Cbz piperazine-4-ethyl formate are used as substrates to react to obtain a compound B9 with a structure shown in formula II;

in the preparation process of the compound B9, the addition molar ratio of the N, O-dimethylhydroxylamine hydrochloride, the isopropyl magnesium chloride and the N-Cbz piperazine-4-ethyl formate is 1-1.2:2-2.2: 1;

preferably, the compound B9 is prepared by mixing and reacting the N, O-dimethylhydroxylamine hydrochloride with isopropyl magnesium chloride at 0-4 ℃, then adding N-Cbz piperazine-4-ethyl formate, and separating after the reaction is finished to obtain the compound B9.

4. The method according to claim 2, wherein the preparation of compound B4 comprises: under the inert gas atmosphere, 3, 4-methylenedioxybromobenzene and n-butyllithium are mixed and reacted at the temperature of-70 to-80 ℃, then a compound B9 is added, the temperature is raised for reaction, and the compound B4 is obtained by separation;

preferably, the molar ratio of the 3, 4-methylenedioxybromobenzene to the n-butyl lithium to the compound B9 is 1-1.1: 1-1.2: 1;

preferably, the mixture reacts for 20 to 30min at the temperature of between 70 ℃ below zero and 80 ℃ below zero, and the temperature is increased for 2 to 3 h;

preferably, the separation comprises extraction, washing, drying and chromatography; preferably, the extractant is ethyl acetate, and the washing is performed by using a sodium bicarbonate solution and then a sodium chloride solution; preferably, the inert gas is nitrogen or argon.

5. The preparation method according to claim 2, characterized in that ethylene glycol, imidazole and tert-butyldimethylsilyl chloride are reacted to obtain a compound B2 having a structure shown in formula IV;

6. The method according to claim 5, wherein the preparation of compound B3 comprises: under the nitrogen range, mixing the compound B2 with 4-bromophenol and triphenylphosphine, cooling to-4-0 ℃, adding diisopropyl azodicarboxylate, and separating after reaction to obtain a compound B3;

preferably, the compound B2, 4-bromophenol, triphenylphosphine and diisopropyl azodicarboxylate are added in a molar ratio of 1-1.2:1-1.2:2-2.2: 2-2.2.

7. The method according to claim 6, wherein the preparation of compound B5 comprises: mixing the compound B3 with the n-butyllithium under the nitrogen atmosphere and at the temperature of-70 to-80 ℃, and reacting for 30-40 min; then adding a compound B4, heating for reaction, and separating to obtain a compound B5;

preferably, the mixing molar ratio of the compound B3, the n-butyl lithium and the compound B4 is 1-1.1: 1.2-1.3: 1; preferably, compound B3 is reacted with a solution of n-butyllithium in hexane in tetrahydrofuran solvent; preferably, the reaction time after the compound B4 is added is 3-4h, and the temperature is naturally raised.

8. The method according to claim 2, wherein the preparation of compound B7 comprises: under the environment of triethylamine and dichloromethane, mixing the compound B6 with 4-nitrophenol chloroformate for reaction, heating for reaction, and separating to obtain a compound B7;

preferably, 4-nitrophenol chloroformate is mixed with said compound B6 in a molar ratio of 1.2 to 1.4:1 at 0 to 4 ℃;

preferably, the preparation of compound B8 comprises: mixing the compound B7 with tetrabutylammonium fluoride for reaction to obtain a compound B8;

preferably, the mixing molar ratio of the compound B7 to tetrabutylammonium fluoride is 1: 3-3.2; preferably, the mixing reaction time is 3-4h, and the separation is carried out after the mixing reaction.

9. Use of the pharmaceutical intermediate of claim 1 for the preparation of a monoacylglycerol lipase-targeted PROTAC molecule or an antitumor drug.

10. A monoacylglycerol lipase PROTAC protein degradation compound comprising a first ligand and a second ligand, and the first ligand is linked to the second ligand through a linker, the first ligand having the structure of the pharmaceutical intermediate of claim 1 or the structure of the pharmaceutical intermediate of claim 1 in which a hydroxyl group is substituted; the second ligand is an E3 ubiquitin ligase ligand;

the monoacylglycerol lipase PROTAC protein degradation compound has a structure shown in formula XI:

formula XI:

preferably, the second ligand is selected from: a ligand targeting VHL, CRBN, MDM2 or IAPE e3 ubiquitin ligase complex; preferably, the second ligand is selected from the group consisting of a ligand of MDM 2; the linker is selected from a linear or branched molecule; preferably, the linker is selected from polyethylene glycol;

formula XII: